~85% to 90% of patients with BPDCN present with skin lesions1-3
Dermatologists may be the first to recognize the signs of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and biopsy suspicious lesions4-6
The CD123 marker is highly expressed (~95%) on BPDCN cells1,5,7
Pathologists can test for BPDCN by including CD123, in combination with CD4 and CD56, in every hematologic diagnostic panel4,8*
Left untreated, BPDCN may rapidly progress to an acute leukemic disease7,9
Hematologist-Oncologists can accurately diagnose BPDCN, differentiating it from more common cancers with similar presentations1,4,9,10
Early diagnosis of this deadly cancer is critical and may take a multidisciplinary team4
*BPDCN can include other markers, such as TCL1, TCF4, and CD303 (BDCA2).4,11
BPDCN = blastic plasmacytoid dendritic cell neoplasm.
References: 1. Laribi K, et al. Blastic plasmacytoid dendritic cell neoplasm: from origin of the cell to targeted therapies. Biol Blood Marrow Transplant. 2016;22(8):1357-1367. 2. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016(1):16-23. 3. Julia F, et al. Blastic plasmacytoid dendritic cell neoplasm: clinical features in 90 patients. Br J Dermatol. 2013;169(3):579-586. 4. Pagano L, et al. Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approaches. Br J Haematol. 2016;174(2):188-202. 5. Facchetti F, et al. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98-111. 6. Shapiro R, et al. Blastic plasmacytoid dendritic cell neoplasm: a review of diagnosis, pathology, and therapy. J Cell Sci Ther. 2015;S8:008.doi:10.4172/2157-7013.S8-008. 7. Pagano L, et al. Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. Haematologica. 2013;98(2):239-246. 8. Pemmaraju N, Konopleva M. Treating blastic plasmacytoid dendritic cell neoplasm. The Hematologist website. http://www.hematology.org/Thehematologist/Ask/8927.aspx. Published August 28, 2018. Accessed February 5, 2020. 9. Riaz W, et al. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy. Cancer Control. 2014;21(4):279-289. 10. Goyal A, et al. Blastic plasmacytoid dendritic cell neoplasm. In: Carter JB, et al, eds. Atlas of Cutaneous Lymphomas: Classification and Differential Diagnosis. Cham, Switzerland: Springer International; 2015:193-203. 11. Ceribelli M, Hou ZE, Kelly PN, et al. A druggable TCF4- and BRD4-dependent transcriptional network sustains malignancy in blastic plasmacytoid dendritic cell neoplasm. Cancer Cell. 2016;30(5):764-778.